What is the process for a bone‑marrow (hematopoietic stem‑cell) transplant?

Bone Marrow (Hematopoietic Stem Cell) Transplant Process

The bone marrow transplant process involves five sequential phases: donor selection and HLA typing, stem cell mobilization and collection, conditioning (preparative) chemotherapy ± radiation, stem cell infusion, and engraftment with supportive care.

Phase 1: Donor Selection and HLA Typing

The first critical step is identifying an appropriate donor through comprehensive HLA typing:

• HLA-identical siblings are the preferred donor source, followed by matched unrelated donors (MUD) using high-resolution molecular typing for HLA-A, B, C, DRB1, and DQB1 loci 1, 2
• Donor age and CMV serostatus should be factored into selection when balancing non-relapse mortality versus relapse risk 2
• For matched unrelated donors, younger donors may provide superior disease-free survival compared to older HLA-identical siblings 2
• Alternative donors (haploidentical or mismatched unrelated) are considered when no matched donor is available within a reasonable timeframe 2
• Unrelated cord blood should be used cautiously due to poor outcomes in certain diseases and only when no other suitable donor exists 2

Common pitfall: Delaying transplant while searching for a "perfect" donor can allow disease progression. Once a suitable matched donor is identified, proceed expeditiously.

Phase 2: Stem Cell Mobilization and Collection

For autologous transplants and peripheral blood stem cell collection:

• Mobilization typically uses high-dose cyclophosphamide followed by filgrastim (G-CSF) to move hematopoietic stem cells from bone marrow into peripheral blood 3
• The median time to best response is 4-5 cycles for mobilization agents 2
• Stem cells are collected via leukapheresis from the circulation after mobilization 3
• Some centers perform ex vivo lymphocyte depletion using immunomagnetic selection 3
• Peripheral blood is the recommended stem cell source for HLA-matched sibling and unrelated donor transplants due to faster engraftment, though it carries higher GVHD risk 2, 4
• Bone marrow grafts remain indicated for severe aplastic anemia and certain non-malignant disorders due to lower GVHD risk 4

Quality control: Grafts undergo sterility testing and verification of adequate HSC and hematopoietic progenitor content before cryopreservation 3.

Phase 3: Conditioning (Preparative) Regimen

Before stem cell infusion, patients receive conditioning therapy:

• Myeloablative conditioning (MAC) without irradiation should be used for standard transplantation when patients are fit enough 1
• Intravenous busulfan formulation is preferred in busulfan-containing regimens 1
• The conditioning intensity balances non-relapse mortality (higher with intensive regimens) against relapse risk (higher with reduced intensity) 2
• For fit patients, myeloablative conditioning is preferred over reduced intensity conditioning, particularly in diseases with high relapse rates 2
• In allogeneic transplants, conditioning eradicates malignant bone marrow cells and induces immunosuppression for donor cell engraftment 4
• In autologous transplants, high-dose myeloablative therapy treats the malignancy before rescue with the patient's own cells 4

Critical consideration: Reduced toxicity regimens are under investigation but should only be used within clinical trials 1.

Phase 4: Stem Cell Infusion

The actual transplant procedure:

• Cryopreserved stem cells are thawed and infused intravenously similar to a blood transfusion 3
• The infusion itself is relatively straightforward compared to the surrounding procedures
• Cells naturally home to bone marrow niches where they establish residence 5

Phase 5: Engraftment and Post-Transplant Management

The recovery period requires intensive supportive care:

GVHD Prophylaxis (Allogeneic Transplants)

• Cyclosporine plus methotrexate (IV on days +1, +3, +6, +11) represents the gold standard for GVHD prophylaxis from matched sibling donors 1
• Add ATG or alemtuzumab for unrelated or HLA-partially matched donors 1

Growth Factor Support

• G-CSF (filgrastim or sargramostim) expedites neutrophil recovery after autologous transplant, though impact on survival is mixed 6, 4
• Patients already receiving prophylactic filgrastim/sargramostim should continue; do not add pegfilgrastim therapeutically 6
• For therapeutic use in febrile neutropenia, only filgrastim or sargramostim should be used (not pegfilgrastim) 6

Monitoring and Complications

• Chimerism and minimal residual disease (MRD) monitoring guide post-transplant management 2
• Neutrophil recovery typically occurs within 2-3 weeks for peripheral blood grafts
• Close monitoring for infections, GVHD (allogeneic), and disease relapse is essential
• Iron overload control is critical for optimal outcomes, particularly in thalassemia patients 1

Key Procedural Nuances

Timing considerations: Once identified as a transplant candidate, upfront transplantation without prior disease-modifying treatment is preferred when a suitable donor is available 2. Pre-transplant debulking with chemotherapy risks disease progression, worsening cytopenias, or complications that may prevent proceeding to transplant 2.

Age considerations: Experience in adult patients (>18 years) remains limited with transplant-related mortality around 25%, emphasizing the importance of patient selection 1.

Standards compliance: All mobilization, collection, and storage procedures must meet national regulatory standards and international accreditation requirements 3.